Skip to Main Content

Richard Horgan has waited for this moment for more than three years.

Last month, the Food and Drug Administration granted permission for his younger brother Terry, 27, who lives with muscular dystrophy, to receive a first-of-its-kind gene therapy that was tailor-made for his genetic mutation.


When the infusion of the drug happens at UMass Chan Medical School, it will be an emotional moment for Terry and Richard, the driving force behind the experimental drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.